Anixa Biosciences Reported In-line with Estimates

Anixa Biosciences (ANIX) reported a loss of $0.08 per share on revenue of $0.00 million for the fiscal third quarter ended July 2026. The consensus estimate was a loss of $0.08 per share. The company reported in-line with consensus estimates.

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.